Fig. 3From: Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancerPEPDG278D induction of EGFR degradation is slowed by EGFR ligands. a Western blotting of whole cell lysates from untreated cells, cells treated with PEPDG278D (25 nM) for different times in medium containing 10% FBS, no FBS, or HB-EGF (20 ng/ml) without FBS, or from cells treated with HB-EGF (20 ng/ml) without PEPDG278D and FBS. b Confocal fluorescence staining of EGFR, PEPDG278D and nuclei (DAPI) in SW48 cells treated with PEPDG278D (25 nM) for 15 min or 6 h. c Confocal fluorescence staining of EGFR, LAMP1 and nuclei (DAPI) in SW48 cells with no treatment, or treated with PEPDG278D (25 nM) and/or chloroquine (25 μM) for 1 or 6 h. Scale bars in b, c: 10 μmBack to article page